2014
DOI: 10.1136/ejhpharm-2013-000436.449
|View full text |Cite
|
Sign up to set email alerts
|

PS-099 Pharmaceutical intervention: enoxaparin use recommendations in patients with renal impairment

Abstract: Background Enoxaparin is a low molecular weight heparin used in the treatment and prophylaxis of thromboembolic disease. It is metabolised in the liver and its elimination is mainly renal. Renal impairment results in a decrease in its elimination and then in a higher anticoagulant response. In patients with severe renal impairment dosage adjustment is recommended. Purpose To analyse enoxaparin dose adjustment in patients with severe renal impairment based on clinical practice guideline recommendations. Mat… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles